WEBULL
News
OCS
28.48
+3.60%
0.99
Weekly Report: what happened at OCS last week (0126-0130)?
Weekly Report · 02/02 10:22
Weekly Report: what happened at OCS last week (0119-0123)?
Weekly Report · 01/26 10:21
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 01/21 17:10
Weekly Report: what happened at OCS last week (0112-0116)?
Weekly Report · 01/19 10:28
Weekly Report: what happened at OCS last week (0105-0109)?
Weekly Report · 01/12 10:27
J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks
TipRanks · 01/08 11:04
Oculis To Present Late-Stage Pipeline Progress Including Breakthrough Therapy And Phase 3 Milestones At 2026 J.P. Morgan Healthcare Conference
Benzinga · 01/08 09:29
Oculis (OCS): Privosergtor’s Breakthrough Profile in Optic Neuritis Supports First-in-Class Upside and Buy Rating
TipRanks · 01/06 18:15
Oculis: Strengthening Clinical and Regulatory Momentum Supports Buy Rating and $42 Target
TipRanks · 01/06 17:05
Oculis gains on FDA breakthrough therapy status for optic neuritis therapy
Seeking Alpha · 01/06 16:19
S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge
Barchart · 01/06 15:34
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
Benzinga · 01/06 15:07
Morning Movers: OneStream surges following report of Hg takeover talks
TipRanks · 01/06 14:01
Oculis up 9% after announcing breakthrough therapy designation for Privosegtor
TipRanks · 01/06 12:55
Stocks Supported by AI Investment and Strength in Miners
Barchart · 01/06 10:09
Why Oculis Is Rising In Pre-market?
NASDAQ · 01/06 09:50
Oculis Secures FDA Breakthrough Therapy Designation For Privosegtor In Optic Neuritis As PIONEER Program Targets $7B US Neuroprotective Market
Benzinga · 01/06 09:11
Stocks Edge Higher on Strength in Chip Makers and Data Storage Companies
Barchart · 01/06 09:08
Weekly Report: what happened at OCS last week (1229-0102)?
Weekly Report · 01/05 10:21
Weekly Report: what happened at OCS last week (1222-1226)?
Weekly Report · 12/29/2025 10:20
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.